AI + EXCLUSIVE DATA

AI tracks executive moves from sources others don't have

Our proprietary AI analyzes exclusive hiring data to find decision-makers actively evaluating solutions like yours.

10-25 executive leads daily • Direct contact info • First 90 days targeting

Start with:

✓Flexible Plans • $39/mo or $29/mo annual

✓AI + proprietary hiring database

✓Executive contact details included

INDUSTRY FIRST

Deciphera Pharmaceuticals Announces Retirement of Daniel L. Flynn, Ph.D., and Appointment of Dashyant Dhanak, Ph.D., As Executive Vice President and Chief Scientific Officer

Aug 03, 2023•about 2 years ago

Position

Chief Scientific Officer

Company

Deciphera Pharmaceuticals

Dashyant Dhanak

WalthamTherapeuticsBiotechnologyHealth Care

Description

Deciphera Pharmaceuticals, Inc. , a biopharmaceutical company focused on discovering, developing, and commercializing important new medicines to improve the lives of people with cancer, today announced that the Company’s Founder, Executive Vice President, and Chief Scientific Officer, Daniel L. Flynn, Ph.D., will retire effective September 5, 2023 and will transition to a role as Senior Advisor to the Company

Company Information

Company

Deciphera Pharmaceuticals

Location

Waltham, Massachusetts, United States

About

Deciphera is a biopharmaceutical company focused on discovering, developing, and commercializing important new medicines to improve the lives of people with cancer. We are leveraging our proprietary switch-control kinase inhibitor platform and deep expertise in kinase biology to develop a broad portfolio of innovative medicines. In addition to advancing multiple product candidates from our platform in clinical studies, QINLOCK® is Deciphera’s switch-control inhibitor for the treatment of fourth-line GIST. QINLOCK is approved in Australia, Canada, China, the European Union, Hong Kong, Israel, Macau, New Zealand, Singapore, Switzerland, Taiwan, the United Kingdom, and the United States.

Company News

(10 articles)

Mon, 28 Jul 2025 07:00:00 GMT

Deciphera Announces Positive CHMP Opinion for ROMVIMZA™ (vimseltinib) for the Treatment of Tenosynovial Giant Cell Tumor (TGCT) - Yahoo Finance

Fri, 14 Feb 2025 08:00:00 GMT

U.S. FDA Grants Full Approval of Deciphera’s ROMVIMZA™ (vimseltinib) for the Treatment of Symptomatic Tenosynovial Giant Cell Tumor (TGCT) - Business Wire

Fri, 14 Feb 2025 08:00:00 GMT

FDA approves Ono's rare tumor drug from $2.4B Deciphera buyout - Fierce Pharma

Tue, 30 Apr 2024 07:00:00 GMT

ONO Enters into a Definitive Agreement to Acquire Deciphera Pharmaceuticals - PR Newswire

Mon, 29 Apr 2024 07:00:00 GMT

Ono Pharmaceutical acquires cancer-focused biopharma Deciphera for $2.4bn - Pharmaceutical Technology

Wed, 12 Jun 2024 07:00:00 GMT

Ono Acquires Deciphera Pharmaceuticals - Contract Pharma

Mon, 29 Apr 2024 07:00:00 GMT

Deciphera to sell for $2.4B, adding to upswing in biopharma M&A - BioPharma Dive

Mon, 29 Apr 2024 07:00:00 GMT

Deciphera Pharmaceuticals to be Acquired by ONO Pharmaceutical For $2.4 Billion - Stock Titan

Fri, 26 Apr 2024 07:00:00 GMT

Diving Into Deciphera Pharmaceuticals (NASDAQ:DCPH) - Seeking Alpha

Mon, 29 Apr 2024 07:00:00 GMT

Deciphera Pharmaceuticals Stock Soars 72%. It’s Being Acquired. - Barron's

FundzWatch™ Score

Medium Activity

Related People

Executive Insights

Based on hiring data

New executive impact window

87% of new executives make significant technology decisions within first 100 days

Budget influence

C-level executives control 73% of technology spending decisions

Transformation catalyst

65% of new senior hires launch digital transformation initiatives

Vendor review timeline

New executives typically review existing vendors within 6 months